The review study by Porth et al. concluded that SGLT-2 inhibitors have been shown to improve glycemic indices, reduce body weight and total fat mass, lower total testosterone and dehydroepiandrosterone sulfate (DHEAS) levels, and restore menstrual cycles in patients with PCOS [35]. The gene discussed is SLC5A2; the disease is polycystic ovary syndrome.